bluebird bio, Inc.
BLUEDelisted Jun 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001293971
bluebird bio, Inc. was delisted on Jun 2, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 85 institutions reported holding it in 13F filings for Q1 2025, worth $17.1M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in bluebird bio, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
BLUE is no longer listed, so this page shows Q1 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 85
- +4 vs. Q4 2024
- Shares held
- 3.50M
- +659.2K (+23.2%) vs. Q4 2024
- Total value
- $17.1M
- −$6.60M (−27.8%) vs. Q4 2024
- New holders
- 22
- 15 more added
- Sold out
- 18
- 24 more reduced
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLUE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 3 | $6.89K |
| Q1 2025 | 85 | $17.1M |
| Q4 2024 | 83 | $23.8M |
| Q3 2024 | 140 | $32.9M |
| Q2 2024 | 152 | $77.2M |
| Q1 2024 | 159 | $131.6M |
| Q4 2023 | 188 | $180.2M |
| Q3 2023 | 170 | $272.7M |
| Q2 2023 | 177 | $308.6M |
| Q1 2023 | 180 | $309.5M |
| Q4 2022 | 186 | $470.5M |
| Q3 2022 | 163 | $414.9M |
| Q2 2022 | 156 | $227.9M |
| Q1 2022 | 178 | $300.5M |
| Q4 2021 | 176 | $581.9M |
| Q3 2021 | 200 | $996.6M |
| Q2 2021 | 235 | $1.70B |
| Q1 2021 | 235 | $1.58B |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding bluebird bio, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Fairfield Financial Advisors, LTD | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |